前列腺癌切缘阳性或包膜外侵犯患者根治性前列腺切除术后辅助放疗对比单纯根治性前列腺切除术的随机试验
这项随机、开放标签、平行组试验纳入250例切缘阳性或包膜外侵犯的前列腺癌患者,比较根治性前列腺切除术后辅助放疗与单纯手术的疗效和耐受性;辅助放疗组10年生化复发无生存率为82%,观察组为61%(HR 0.26,P<0.001),总生存无显著差异(92% vs 87%,HR 0.69,P=0.4),辅助放疗组3级不良事件更多(56% vs 40%,P=0.016)。
要点
- 辅助放疗组10年生化复发无生存率82%,观察组61%(HR 0.26,95%CI 0.14-0.48,P<0.001)。
- 辅助放疗组10年总生存率92%,观察组87%(HR 0.69,95%CI 0.29-1.60,P=0.4),无显著差异。
- 辅助放疗组3级不良事件发生率56%,观察组40%(P=0.016)。
核心结论
- 根治性前列腺切除术后辅助放疗总体耐受良好,与单纯手术相比延长了切缘阳性或包膜外侵犯患者的生化复发无生存期。
研究设计与样本
- 随机、开放标签、平行组试验,2004年4月至2012年10月在8家芬兰医院纳入250例pT2切缘阳性或pT3a、pN0、M0且无精囊侵犯的前列腺癌患者。
- 126例患者接受辅助放疗,剂量66.6Gy。
主要发现
- 随访结束时存活患者的中位随访时间辅助组为9.3年,观察组为8.6年。
- 10年生化复发无生存率辅助组82%,观察组61%(HR 0.26,95%CI 0.14-0.48,P<0.001)。
- 10年总生存率辅助组92%,观察组87%(HR 0.69,95%CI 0.29-1.60,P=0.4)。
- 转移性癌症分别发生2例和4例。
- 观察组43例生化复发患者中37例接受了挽救性放疗。
局限性
- 本研究的一项局限性是患者数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy. OBJECTIVE: To compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: This was a randomised, open-label, parallel-group trial. A total of 250 patients were enrolled between April 2004 and October 2012 in eight Finnish hospitals, with pT2 with positive margins or pT3a, pN0, M0 cancer without seminal vesicle invasion. INTERVENTION: A total of 126 patients received adjuvant radiotherapy at 66.6Gy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was biochemical recurrence-free survival, which we analysed using the Kaplan-Meier method and Cox proportional hazard regression. Overall survival, cancer-specific survival, local recurrence, and adverse events were secondary endpoints. RESULTS AND LIMITATIONS: The median follow-up time for patients who were alive when the follow-up ended was 9.3yr in the adjuvant group and 8.6yr in the observation group. The 10-yr survival for biochemical recurrence was 82% in the adjuvant group and 61% in the observation group (hazard ratio [HR] 0.26 [95% confidence interval {CI} 0.14-0.48], p<0.001), and for overall survival 92% and 87%, respectively (HR 0.69 [95% CI 0.29-1.60], p=0.4). Two and four metastatic cancers occurred, respectively. Out of the 43 patients with biochemical recurrence in the observation group, 37 patients received salvage radiotherapy. In the adjuvant group, 56% experienced grade 3 adverse events, versus 40% in the observation group (p=0.016). Only one grade 4 adverse event occurred (adjuvant group). A limitation of this study was the number of patients. CONCLUSIONS: Adjuvant radiotherapy following radical prostatectomy is generally well tolerated and prolongs biochemical recurrence-free survival compared with radical prostatectomy alone in patients with positive margins or extracapsular extension. PATIENT SUMMARY: Radiotherapy given immediately after prostate cancer surgery prolongs prostate-specific antigen progression-free survival, but causes more adverse events, when compared with surgery alone.
引用
- Hackman G, Taari K, Tammela TL, et al. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. Eur Urol. 2019. PMID: 31375279. doi:10.1016/j.eururo.2019.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。